Archives
-
Cycloheximide in Protein Turnover and Antiviral Research
2026-10-06
A source-grounded overview of Cycloheximide as a protein biosynthesis inhibitor, examining its conceptual value in protein turnover studies, apoptosis research, and interpretation of antiviral iron-homeostasis findings while distinguishing direct evidence from supplier claims.
-
CX-5461: Evidence, Mechanisms, and Research Context
2026-10-06
CX-5461 is a research compound used to investigate RNA polymerase I inhibition, ribosome biogenesis stress, DNA damage, and cancer cell fate. Recent cervical cancer findings support further preclinical study, while broader claims about solid tumor growth inhibition, autophagy, and senescence remain model- and source-dependent.
-
Oleic Acid: Evidence, Scope, and Limitations
2026-10-05
A source-grounded overview of Oleic Acid and C18:1(9Z), using a 2024 preclinical study to explain lipid-signaling principles, evidence quality, interpretation, applicability, and key limitations.
-
Necrosulfonamide in Necroptosis Research
2026-10-05
Necrosulfonamide (NSA) is a pharmacological tool used to investigate MLKL-dependent necroptosis. The 2025 study by Liu et al. identified an ONOO−–ER stress–IP3R–mitochondrial calcium axis in hyperhomocysteinemia-associated cardiac microvascular ischemia–reperfusion injury, but it did not directly establish NSA as an intervention in that model. This overview compares the study’s upstream calcium findings with the conceptual value and limitations of an MLKL-directed probe.
-
Phenothiazines, ROS, and Macrophage Defense
2026-10-04
Qiu et al. report that phenothiazines strengthen macrophage antibacterial activity through linked increases in reactive oxygen species, lysosomal activity, and autophagy. The study supports a host-directed therapeutic concept, while its findings do not by themselves establish dopamine D2 receptor dependence or clinical efficacy.
-
Mtb, BMX Kinase, and Lysosomal Acidification
2026-10-03
A 2026 Nature Communications study identifies a host-pathogen mechanism in which Mycobacterium tuberculosis uses the secreted protein Chp2/Rv1184 to promote BMX-dependent phosphorylation of ATP6V1E1, weakening V-ATPase assembly and lysosomal acidification. The findings connect a bacterial effector, host kinase signaling, and intracellular survival, while supporting—but not yet proving—the therapeutic concept of targeting lysosomal regulation in tuberculosis.
-
Intravesical p21 mRNA–LNP Therapy for Bladder Cancer
2026-10-02
A 2026 FASEB Journal study developed chemically modified p21 mRNA packaged in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, inhibited tumor-cell growth, and reduced orthotopic tumor progression while limiting systemic exposure, supporting localized mRNA delivery as a tumor-suppressor replacement strategy.
-
PF-573228 FAK Inhibitor: Mechanotransduction Workflow
2026-10-01
Use PF-573228 to connect matrix mechanics with FAK-dependent phosphorylation, migration, angiogenesis, and dentinogenic phenotypes. This practical workflow combines dose-aware treatment, matched-stiffness controls, orthogonal readouts, and troubleshooting guidance for mechanotransduction and cancer research.
-
Leucomycin’s In Vitro Antibacterial Activity
2026-10-01
Iwata and Akiba developed a systematic in vitro analysis of leucomycin, emphasizing its A1 fraction, activity against resistant staphylococci, and sensitivity to medium conditions. The study provides a useful historical framework for interpreting macrolide susceptibility, fraction-specific activity, and the limits of transferring older antibacterial data to modern research workflows.
-
Streptavidin-HyperFluor™ 647: Lab Guide
2026-09-30
A scenario-based guide to using Streptavidin-HyperFluor™ 647 (SKU K4406) for biotin-dependent fluorescence detection in viability, proliferation, cytotoxicity, imaging, and flow workflows. It explains assay compatibility, optimization, interpretation, and practical vendor-selection criteria without overstating product-specific performance.
-
IR-1061 Near Infrared Fluorescent Dye Workflow
2026-09-30
IR-1061 combines 1064 nm emission with a formulation strategy suited to deep-tissue and vascular imaging. This practical guide covers DMSO handling, carrier optimization, aggregation control, assay design, and troubleshooting for reliable NIR-II results.
-
Isoproterenol sulfate dihydrate in Cell Assays
2026-09-29
A scenario-based guide to using Isoproterenol sulfate dihydrate (SKU C6402) in beta-adrenergic stimulation, viability, proliferation, and human cardiac assembloid workflows. It connects formulation, preparation, assay interpretation, and vendor-selection decisions to practical laboratory controls.
-
DFO (9H-1,8-Diazafluoren-9-one) Guide
2026-09-29
DFO, also called 9H-1,8-Diazafluoren-9-one, is a fluorescent reagent for amino-acid-based latent fingerprint detection. Its documented solubility, light sensitivity, purity, and porous-substrate use define practical handling boundaries for forensic laboratories.
-
Fenipentol: An Identity-First Assay Strategy
2026-09-28
Fenipentol and 1-Phenyl-1-pentanol are examined through an identity-first framework that separates compound-specific evidence from findings on the positional isomer 1-phenyl-2-pentanol. This guide translates historical secretory observations, ESR1 docking data, and modern cell-based methods into practical assay decisions.
-
ATRX Loss and RTK Inhibitor Sensitivity in Glioma
2026-09-28
Pladevall-Morera and colleagues report that ATRX-deficient high-grade glioma cells are more sensitive to several receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient cells, and that combining RTK inhibition with temozolomide produces pronounced toxicity in the deficient cells. The findings make ATRX status a relevant variable for preclinical drug testing and for interpreting RTK-inhibitor trials, while leaving clinical benefit and the underlying sensitivity mechanism to be established.